Rubraca (rucaparib)

  • Innovator Brand Name: Rubraca
  • API: Rucaparib Camsylate
  • Packaging: Tablets
  • Strength: 200 mg/250 mg/300 mg

Rucaparib Camsylate is a poly (ADP-ribose) polymerase (PARP) inhibitor used to treat adult patients with certain types of prostate cancer or ovarian epithelial, fallopian tube, or primary peritoneal cancer. Rucaparib is a type of PARP inhibitor, and also called AG014699, PARP-1 inhibitor AG014699. This PARP inhibitor is also being studied in the treatment of certain other types of cancer.

The recommended dose is 600 mg (two 300 mg rucaparib tablets) taken by mouth twice daily with or without food, for a total daily dose of 1,200 mg. Continue treatment of Rucaparib until the disease is progressive or unacceptable toxicity occurs. 

If any patient misses a dose of Rucaparib, instruct the patient to take the very next dose at its scheduled time. Puked doses should not be replaced. 

Patients receiving Rucaparib for mCRPC should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy. 

Most commonly reported rucaparib side effects among patients with ovarian cancer are nausea, fatigue, AST/ALT elevation, vomiting, anemia, dysgeusia, constipation, decreased appetite, diarrhea, rash, thrombocytopenia, neutropenia, stomatitis, nasopharyngitis/URI, abdominal pain/distention, and dyspnea.

Most commonly reported side effects among patients with BRCA-mutated mCRPC are fatigue, nausea, anemia, decreased appetite, vomiting, diarrhea, ALT/AST increased, constipation, and thrombocytopenia. 

  • Acute Myeloid Leukemia (AML)/Myelodysplastic Syndrome (MDS) may occur in patients treated with rucaparib 300 mg, and are potentially fatal adverse reactions. The time-span of treatment prior to the diagnosis of MDS/AML ranged from one month to around  53 months.
  • Do not initiate rucaparib treatment until patients have recovered from hematological toxicity due to previous chemotherapy (≤ Grade-1). Assess complete blood counts (CBC) for cytopenia at baseline and monthly thereafter for clinically significant changes throughout the therapy. 
  • For prolonged hematological toxicities (> 4 weeks), interrupt rucaparib uses or reduce dose and assess blood counts weekly until recovery. In case the levels have not recovered to Grade-1 or less after four weeks or if AML/MDS is suspected, refer the patient to a hematologist for further assessment, including analysis of bone marrow and blood sample for cytogenetics. In case AML/MDS is confirmed, discontinue treatment.
  • The medicine Bdparib (rucaparib) can cause fetal harm if used by a pregnant woman based on its working and outcomes from animal studies. The respective females of reproductive age should opt effective contraception throughout treatment and for six months after the final dose. 

Depending on findings from animal reproduction studies and genetic toxicity, male patients with female partners of reproductive age or who are pregnant should opt for effective contraception throughout therapy and for three months after the final dose of rubraca.

Is Rucaparib approved by the FDA?

The FDA first approved Rucaparib on December 19, 2016 to treat patients with advanced ovarian cancer. 

What class of drug is Rucaparib?

Rucaparib is in a class of drugs called poly (ADP-ribose) polymerase (PARP) inhibitors. It is designed to work by destroying or killing cancer cells.

Which PARP inhibitors are approved by the FDA?

There are 3 PARP inhibitors that are approved by the FDA in multiple settings of ovarian cancer:

  • olaparib (Lynparza; AstraZeneca)
  • rucaparib (Rubraca; Clovis Oncology)
  • niraparib (Zejula; GlaxoSmithKline) 

How is Rucaparib supplied?

Rucaparib is supplied as a tablet that you swallow. You’ll likely take Rucaparib twice daily. It’s available in three strengths:

  • Rucaparib 200 mg (milligrams) 
  • Rucaparib 250 mg (milligrams)
  • Rucaparib 300 mg (milligrams)

How to store Rucaparib?

Store this medicinal product at temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

What should one do if someone takes an overdose of Rucaparib?

There is no specific treatment in the event of Rucaparib overdose, and signs/symptoms of drug overdose are not established. In the event of suspected drug overdose, health specialists should consider general supportive measures and should treat symptomatically.

Where can I get Rucaparib at the best price in India?

In order to get the best price of rucaparib in India, always buy/procure this medicinal product from Indian Generic Medicines, which is certified by higher authorities like WHO-GDP, & ISO 9001:2008. 

How much does Rucaparib cost? 

If you want to order or check rucaparib cost, we request you to Call/WhatsApp Us: (+91) 8130290915, Or dial our TOLL-FREE: 1800-889-1064, Or Write Us:

Is the drug Rucaparib available in India?

Rucaparib is a (prescription drug, doctor-prescribed medication, or health care professional-prescribed medicine) pharmaceutical drug that can be legally dispensed against a medical prescription.

Rucaparib can be made available through the network of authorized distributors in India. (Ahmedabad, Mumbai, Kolkata, Hyderabad, Chennai, Delhi, Bangalore, Pune, etc.)

Can You Send the medicine Rucaparib to Foreign Destinations?

Buy rucaparib from India online at the best/lowest price through a leading supplier. Indian Generic Medicines can assist in the delivery of this medicine; the doctor prescribed medication to the USA, UK, Australia, China, Canada, Saudi Arabia, South Africa, Zambia, Thailand, Sri Lanka, Pakistan, Qatar, Kuwait, Sweden, Hong kong, UAE, Kazakhstan, Turkey, Philippines, Singapore, Afghanistan, Malaysia, Japan, Germany, Uzbekistan Nepal, and many other countries.

Contact Patient Support

If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.






+91 8130290915


CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.

Contact Us On WhatsApp

    Please enter security code below: